FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2022/12/047809 [Registered on: 01/12/2022] Trial Registered Prospectively
Last Modified On: 17/04/2023
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Nutraceutical 
Study Design  Randomized, Parallel Group, Placebo Controlled Trial 
Public Title of Study   A clinical study of nutritional and phytoconstituents supplementation in prediabetic subjects 
Scientific Title of Study   A Randomized, placebo controlled study to assess the efficacy & safety of nutritional and phytoconstituents supplementation in prediabetic subjects 
Trial Acronym  Nil 
Secondary IDs if Any  
Secondary ID  Identifier 
MHC/CT/22-23//007 Version: 1.00 dated 05 Nov 2022  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Shashank Joshi 
Designation  Senior consultant 
Affiliation  Joshi Clinic 
Address  Number twelve,first Floor, Golden Palace, Turner Road, Bandra West, behind Union Bank, Mumbai

Mumbai
MAHARASHTRA
400050
India 
Phone  9820186302  
Fax  -  
Email  shashank.sr@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Rumaiza Mamsa 
Designation  Medical services 
Affiliation  Meyer Organics Pvt. Ltd. 
Address  First floor, Medical service department , A 303 Road No 32 Wagle Estate Thane Mumbai

Mumbai
MAHARASHTRA
400604
India 
Phone  9167846090  
Fax  9162757002  
Email  rmamsa@meyer.co.in  
 
Details of Contact Person
Public Query
 
Name  Neepa Gaba 
Designation  Scientific coordinator 
Affiliation  Meyer Organics Pvt. Ltd. 
Address  First floor, Medical service department , A 303 Road No 32 Wagle Estate Thane Mumbai

Mumbai
MAHARASHTRA
400 604
India 
Phone  912225817126  
Fax  9162757002  
Email  ngaba@meyer.co.in  
 
Source of Monetary or Material Support  
Meyer Organics Pvt Ltd A-303, Road No. 32, Wagle Estate, Thane Mumbai Maharashtra 400 604 India 
 
Primary Sponsor  
Name  Meyer Organics Pvt Ltd 
Address  A-303, Road No. 32, Wagle Estate, Thane Mumbai Maharashtra 400 604 India 
Type of Sponsor  Pharmaceutical industry-Indian 
 
Details of Secondary Sponsor  
Name  Address 
Nil  Nil 
 
Countries of Recruitment     India  
Sites of Study
Modification(s)  
No of Sites = 3  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Jothydev Kesavadev  Jothydevs Diabetes Research Centre   JDC Junction, Konkalam Road, Mudavanmugal Poojappura Trivandrum, Kerala, India- 695032
Thiruvananthapuram
KERALA 
9895040055
-
jothydev@gmail.com 
Dr V G Vaidya  Lokmanya Medical Research Centre and Hospital  Forth floor OPD 401 314 B Telco Road Chinchwad Pune
Pune
MAHARASHTRA 
9822057766
-
vgvclinical@gmail.com 
Dr G Sunil Kumar  SK Clinic and Scans  Govt. Hospital junction, Poovar, Thiruvananthapuram 695525
Thiruvananthapuram
KERALA 
8921830875
-
sun786grg@gmail.com 
 
Details of Ethics Committee
Modification(s)  
No of Ethics Committees= 3  
Name of Committee  Approval Status 
Institutional Ethics Committee Jothydevs Diabetes Research Centre   Approved 
Institutional Ethics Committee Lokmanya Medical Research Centre  Approved 
Royal Pune Independent Ethics Commitee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: R739||Hyperglycemia, unspecified,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Diabetone tablet along with Cinafen plus tablet.  One tablet of each Diabetone and Cinafen plus daily after main meal with lifestyle modifications for 90 days. 
Comparator Agent  Placebo  similar placebo tablets for each Diabeton and Cinafen Plus daily after main meal with lifestyle modifications for 90 days 
 
Inclusion Criteria  
Age From  30.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  1. Male and female subjects of 30 to 60 years of age (both inclusive)
2. BMI ≥28.00-≤35 kg/m2 at screening. (Overweight to obese)
3. Hemoglobin A1c (HbA1c) ≥5.7 % and ≤6.4%.
4. Fasting Plasma Glucose (FPG) between 100-125 mg/Dl both inclusive. 
 
ExclusionCriteria 
Details  1. Subjects with type 1 or type 2 diabetes mellitus (T2DM), gestational diabetes (GDM), or secondary diabetes;
2. Treatment with glucose lowering agent (s) within 90 days before screening.
3. Subjects with elevated liver enzymes AST and/or ALT >3 times of the upper normal limit
4. Subjects with abnormal renal function as measured by eGFR <45ml/min/1.73m2
5. Subjects with BMI more than 35Kg/m2
6. Subjects who had a bariatric surgery.
7. Pregnant or lactating women.
8. Smokers/Alcoholics and/or drug abusers.
9. Subjects with known history or ongoing malignancy.
10. Treatment with immunosuppressive medications in past three months.
11. Subjects suffering from major systemic illness necessitating medical care.
12. Any other reason which can affect the participation of the subject in the study as per investigator’s discretion.  
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Case Record Numbers 
Blinding/Masking   Participant and Investigator Blinded 
Primary Outcome  
Outcome  TimePoints 
1. HbA1c, fasting and post meal plasma glucose levels from screening to end of the study.
2. HOMA-IR score (calculated insulin resistance based on formula with fasting plasma glucose and fasting serum insulin levels) at screening and end of the study. 
Screening to end of the study 
 
Secondary Outcome  
Outcome  TimePoints 
1. Anthropometric parameters like body weight, BMI and % body fat by impendence test at screening and end of the study.
2. Changes in lipid profile at screening and end of the study.
3. Changes in perceived stress score at screening and end of the study.
4. Changes in HRQOL-15D questionnaire score to assess quality of life at screening and end of the study. 
Screening to end of the study 
 
Target Sample Size   Total Sample Size="300"
Sample Size from India="300" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   02/12/2022 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   Nil 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   Prediabetes is the earliest identifiable stage of glucose dysregulation, characterized by plasma glucose levels that are intermediate between normal glucose tolerance and diabetes. In prediabetes there is a disrupted fat metabolism and early stage of disrupted insulin regulation i.e., reduced insulin sensitivity. Obesity is the most powerful yet modifiable risk factor for diabetes.  It is linked with an increased insulin demand and increased likelihood of insulin resistance leading to prediabetes or hyperinsulinemia and then ultimately T2DM. 

Nutritional intervention is important for preventing diabetes, managing existing diabetes & preventing or at least slowing, the rate of development of diabetes complications. Dietary factors are of paramount importance in the management & prevention prediabetes. Balancing the right amount of macronutrients & micronutrients helps us to maintain a healthy diet & a healthy lifestyle. 

Micronutrients serve dual roles: they maintain the stabilization of the cellular structures at their optimal levels, but their inadequacy proceeds to alternate pathways and may cause ailments. These essential micronutrients have important physiological implications and exhibit direct associations with diabetes mellitus. 

Micronutrients are identified as vital nutrients that are required in trace amounts for homeostasis, enzyme regulation and functioning. Macro elements, vitamins, trace elements and organic acids are the four major classes of micronutrients. They enhance insulin action by activating insulin receptor sites. These trace elements play specific roles in the pathogenesis and progression of type 2 diabetes mellitus (T2DM) and the mode of action of a number of macro and trace elements is altered in T2DM. 

A personalized approach for preventing and managing prediabetes should consider biological and behavioral models, and embed nutrition education as part of lifestyle diabetes prevention studies. Functional foods may provide additional benefits in such an approach. 

Phytoconstituents in cinnamon such as cinnamomum aromaticum (Cassia), cinnamomum zeylanicum, etc. have been demonstrated its effect in managing diabetes and metabolic disorder by upregulating glucose uptake, increasing glycogen synthesis, inhibiting glycogen breakdown, and reducing glucose absorption in the small gut. Phytoconstituents in fenugreek namely, diosgenin, 4-hydroxyisoleucine, alkaloid and the fiber component, are the most studied bioactive fractions of the plant, which were found to exert beneficial effects on lowering blood glucose, glucose tolerance, insulin function, inflammatory response, lipid profile, and liver functions.

Diabetone tablets are blend of micronutrients and cinafen plus possess standardized extracts of cinnamon and fenugreek. The present research is an attempt to assess the efficacy & safety of Diabetone and Cinafen plus tablets in subjects with prediabetes. With the present research we can apply the knowledge of pharmacological benefits of micronutrients along with the clinical trials to address the important medical issue of growing prediabetic population to improve glycaemic control, control the disease progression and possibly to reverse the condition. To provide appropriate and timely care to prediabetic subjects, achieve good control of glycemia, reduce the risk of complications related to diabetes, minimise healthcare use, and associated costs by reversing the devastating condition and thereby improving the subjects’ quality of life, it is necessary to begin primary translational work as soon as possible.

As per the macronutrient recommendations for remission and prevention of Diabetes in Asian Indians, with adjusting the proper balance of carbohydrates, protein and fats in diet the remission, and prevention of progression to T2DM is observed.  In line with this study our hypothesis is in longer perspective, micronutrients and phytoconstituents based supplementation will provide good prognosis to the disease with less or no dependency on conventional antidiabetic medication together with reduced or no side effects. Moreover, improved glycemic control will avoid acute decompensation, delay or prevention of microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular complications, reduce mortality, and maintain a good quality of life. A systematic clinical validation of the investigational products in comparison with placebo from the present study will provide a guideline and evidence for care givers and diabetologists to use the standardized nutrition and phytoconstituents in their clinical practice in the management of prediabetes.

 
Close